BioSpace News Archive

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the following virtual investor conferences

Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced the appointment of Molly Harper as Executive Vice President of Operations.

Leading Researchers and Scientists Detail INOVIO’s Proprietary DNA Medicines Technology; Provide Updates on INO-4800 COVID-19 DNA Vaccine and INO-5401 GBM DNA Immunotherapy

Cellular Biomedicine Group Inc. has announced that the 2020 Annual Meeting of Stockholders will be held at 9:00 a.m. Eastern Standard Time on Friday, June 26, 2020, at Aloft Long Island City – Manhattan View, 27-45 Jackson Avenue, Long Island City, New York 11101.

Sexton Biotechnologies pathogen reduced hPL confirmed by PMDA as human derived raw material for regen med products

SQZ Biotechnologies, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that Armon Sharei, PhD, chief executive officer, will be presenting at the following upcoming virtual investor conferences

Dermavant Sciences announced the publication of secondary efficacy and patient-reported outcomes from the Phase 2b randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis in The Journal of the American Academy of Dermatology, the peer-reviewed scientific publication of the American Academy of Dermatology 1.

Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells for the treatment of cancer, announced the appointment of Nathan Jorgensen, PhD, as Chief Financial Officer.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, announced that positive Phase 2 data from its lead pipeline program bomedemstat, will be presented at the Virtual Edition of the 25th EHA Annual Congress beginning June 12, 2020.

ENHERTU is the second innovative oncology medicine to be launched in Japan from the oncology pipeline of Daiichi Sankyo in the past year